Taken together, the inhibitors Y11 and PF-573228, which both target the same Y397 phosphorylation site of FAK, exhibit the most specific therapeutic potential in vitro, since they simultaneously constrained tumor and stroma growth and invasion as a whole, without prominent cytotoxicity (Figure 6, Supplementary Figure S9). This evidence concerns the gene PTK2 and neoplasm.